Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Furthermore -

MNTA Research article - Science Translational Medicine 16 Nov 2016:
Vol. 8, Issue 365, pp. 365ra158

Elucidating the interplay between IgG-Fc valency and Fc?R activation for the design of immune complex inhibitors

Ortiz et al. tested different shapes and sizes of Fc-containing molecules. One particular design, a trimer with a Y-shaped configuration, was particularly effective at binding to Fc? receptors and blocking them without causing inappropriate activation. To demonstrate therapeutic potential, the authors tested this Fc trimer construct in mouse models of three different autoimmune diseases: immune thrombocytopenic purpura, collagen-induced arthritis, and epidermolysis bullosa acquisita, all with promising results.

The Fc trimer, Fc3Y, was highly efficacious in three different animal models of autoimmune diseases. This recombinant molecule may represent an effective therapeutic candidate for Fc?R-mediated autoimmune diseases.

http://stm.sciencemag.org/content/8/365/365ra158